Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Edward Farmer, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Paul Farmer and Mercedes Becerra.
Connection Strength

1.308
  1. Multidrug-resistant tuberculosis and the need for biosocial perspectives. Int J Tuberc Lung Dis. 2001 Oct; 5(10):885-6.
    View in: PubMed
    Score: 0.249
  2. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2000 Feb; 4(2):108-14.
    View in: PubMed
    Score: 0.222
  3. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019 10 24; 367:l5894.
    View in: PubMed
    Score: 0.218
  4. Expanding tuberculosis case detection by screening household contacts. Public Health Rep. 2005 May-Jun; 120(3):271-7.
    View in: PubMed
    Score: 0.080
  5. rpoB gene mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis in northern Lima, Peru. Microb Drug Resist. 2005; 11(1):26-30.
    View in: PubMed
    Score: 0.078
  6. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003 Jan 09; 348(2):119-28.
    View in: PubMed
    Score: 0.068
  7. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001 Aug 04; 358(9279):404-9.
    View in: PubMed
    Score: 0.062
  8. Redefining MDR-TB transmission 'hot spots'. Int J Tuberc Lung Dis. 2000 May; 4(5):387-94.
    View in: PubMed
    Score: 0.056
  9. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis. 2000 Feb; 19(2):132-6.
    View in: PubMed
    Score: 0.055
  10. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis. 1999 Aug; 3(8):643-5.
    View in: PubMed
    Score: 0.054
  11. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998 Nov; 2(11):869-76.
    View in: PubMed
    Score: 0.051
  12. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ. 2012 Jan 01; 90(1):63-6.
    View in: PubMed
    Score: 0.031
  13. Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis. 2011 Oct; 15(10):1294-300.
    View in: PubMed
    Score: 0.030
  14. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6.
    View in: PubMed
    Score: 0.021
  15. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004 Feb 07; 363(9407):474-81.
    View in: PubMed
    Score: 0.018
  16. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001 Jul; 5(7):648-55.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.